Drug-coated stent looks promising in trial:
This article was originally published in Clinica
Biocompatibles International's coronary stent coated with a drug made by Abbott Laboratories looks to be a promising way of preventing restenosis, according to early data from a preclinical trial. The US study involving pigs show that the drug-coated devices lead to a 43% reduction in new tissue growth, with related improvement in internal vessel size and no significant injury or inflammation within the treated artery. Biocompatibles of Farnham, UK, is investigating the use of a number of anti-restenosis pharmaceuticals for use on its stent.